Cherry (C3RY) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
30 Jul, 2026Executive summary
Strategic transformation focused on stabilizing, simplifying, and focusing the business, with Project Blossom driving operational improvements and growth initiatives.
Leadership continuity established with the CEO confirmed and management demonstrating commitment through participation in the rights issue.
Rights issue completed, raising approximately €10.1m to strengthen the balance sheet and support ongoing transformation.
Financial highlights
H1 2026 Group Revenue reached €40.0m, up 3% year-over-year on a comparable basis, despite challenging market conditions.
Gross margin improved significantly from 36.8% to 43.4% year-over-year, driven by cost discipline and improved product mix.
Adjusted EBITDA loss narrowed to €-4.0m in H1 2026 from €-10.2m in H1 2025, reflecting €10m lower costs and strong margin management.
Working capital reduced from €45.1m to €25.3m, highlighting focus on cash generation and operational efficiency.
Q2 2026 Group Revenue was €19.2m (comparable), with adjusted EBITDA improving to €-3.4m from €-7.9m in Q2 2025.
Outlook and guidance
2027 ambition targets break-even for Peripherals at ~€85m revenue and ~44% gross margin.
Key priorities include completing the sale of DH&S, repaying debt, and executing Project Blossom to reduce costs and return to growth.
Clear strategy to stabilize, simplify, and focus, with disciplined execution and strong focus on cash and working capital.
Latest events from Cherry
- Digital Health & Solutions drove revenue growth, but margin pressure and restructuring widened net loss.C3RY
Q2 20249 Jul 2026 - Revenue dropped 25% in H1 2025, with negative EBITDA and liquidity boosted by asset sales.C3RY
Q2 202515 May 2026 - 2025 revenue fell 15% to €94.3m, with restructuring, cost cuts, and segment review ongoing.C3RY
Q4 202512 May 2026 - Revenue fell 17.8% but margins and cash flow improved amid ongoing transformation.C3RY
Q1 20267 May 2026 - 2024 guidance targets €140m–€150m revenue and a 7–8% EBITDA margin, signaling a strong turnaround.C3RY
Investor presentation4 Feb 2026 - Revenue and EBITDA fell short, triggering cost cuts and a revised €120m 2024 outlook.C3RY
Investor presentation4 Feb 2026 - Streamlined for margin-driven growth, with €120M 2024 revenue forecast and €3.5M cost savings.C3RY
Investor presentation4 Feb 2026 - Restructuring, M&A, and operational streamlining target a return to growth and financial stability.C3RY
Investor presentation4 Feb 2026 - Q3 2024 results missed expectations, triggering restructuring and a cut in full-year guidance.C3RY
Q3 2024 TU19 Jan 2026